ES2058653T3 - Inhibidor de proteinasas. - Google Patents

Inhibidor de proteinasas.

Info

Publication number
ES2058653T3
ES2058653T3 ES90106738T ES90106738T ES2058653T3 ES 2058653 T3 ES2058653 T3 ES 2058653T3 ES 90106738 T ES90106738 T ES 90106738T ES 90106738 T ES90106738 T ES 90106738T ES 2058653 T3 ES2058653 T3 ES 2058653T3
Authority
ES
Spain
Prior art keywords
group
butyl
unsubstituted
carbon atoms
benzyloxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90106738T
Other languages
English (en)
Inventor
Naoki Higuchi
Masayuki Saitoh
Hiroshi Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2058653T3 publication Critical patent/ES2058653T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN COMPUESTO INHIBIDOR DE PROTEINASA REPRESENTADO POR LA SIGUIENTE FORMULA GENERAL (1): EN DONDE R1 REPRESENTA UN GRUPO ACILO DE CADENA LINEAL O RAMIFICADA QUE TIENE DE 2 A 10 ATOMOS DE CARBONO, UN GRUPO ALQUILOOXILOCARBOXILO CICLICO RAMIFICADO O POLI-CICLICO QUE TIENE DE 4 A 15 ATOMOS DE CARBONO, UN GRUPO BENCILOOXILOCARBOXILO SUSTITUIDO O NO SUSTITUIDO, UN GRUPO 2,2,2-TRICLOROETILOOXILOCARBONILO, UN GRUPO 2-(TRIMETILOSILILO) ETILOOXILOCARBONILO, UN GRUPO P-TOLUENOSULFONILO, UN GRUPO O-NITROFENILOSULFONILO, UN GRUPO DIFENILOFOSFONOTIOLILO, UN GRUPO TRIFENILOMETILO O UN GRUPO 2-BENZOL-1-METILOVINILO; R2 REPRESENTA UN ATOMO DE HIDROGENO; O R1 Y R2 PUEDEN FORMAR JUNTOS UN GRUPO FENOTALOILO; R3 REPRESENTA UN GRUPO ISOBUTILO, UN GRUPO N-BUTILO O UN GRUPO ISOPROPILO Y EL R1 ANTES MENCIONADO PUEDE SER UN GRUPO BENCILOOXILOCARBONILO NO SUSTITUIDO, CON LA PROVISION DE QUE R3 ES UN GRUPO N-BUTILO; Y R4 REPRESENTA UN GRUPO N-BUTILO.
ES90106738T 1989-04-10 1990-04-09 Inhibidor de proteinasas. Expired - Lifetime ES2058653T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1089904A JP2701932B2 (ja) 1989-04-10 1989-04-10 タンパク質分解酵素阻害剤

Publications (1)

Publication Number Publication Date
ES2058653T3 true ES2058653T3 (es) 1994-11-01

Family

ID=13983709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90106738T Expired - Lifetime ES2058653T3 (es) 1989-04-10 1990-04-09 Inhibidor de proteinasas.

Country Status (7)

Country Link
US (1) US5081284A (es)
EP (1) EP0393457B1 (es)
JP (1) JP2701932B2 (es)
AT (1) ATE108187T1 (es)
DE (1) DE69010375T2 (es)
DK (1) DK0393457T3 (es)
ES (1) ES2058653T3 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
US5510531A (en) * 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
US5475027A (en) * 1990-11-19 1995-12-12 G.D. Searle & Co. Retroviral protease inhibitors
US5614522A (en) * 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
US5708004A (en) * 1990-11-19 1998-01-13 Monsanto Company Retroviral protease inhibitors
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH06506921A (ja) * 1991-02-22 1994-08-04 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー 置換α−アミノアルデヒドおよび誘導体
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
US6511959B1 (en) 1991-06-03 2003-01-28 Norsk Hydro As Use of calcium-activated neutral protease (CANP) inhibitors in pharmaceutical preparations
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3228347B2 (ja) * 1991-06-25 2001-11-12 三菱化学株式会社 シクロプロペノン誘導体
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
ATE160617T1 (de) * 1991-10-14 1997-12-15 Cash Eng Res Einlassregelvorrichtung für verdichter
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
JP2578044B2 (ja) * 1992-03-14 1997-02-05 呉羽化学工業株式会社 フェニルアラニン−グリシン誘導体、その製造方法、及びその誘導体を含有する抗腫瘍剤
AU667376B2 (en) 1992-05-21 1996-03-21 Monsanto Company Retroviral protease inhibitors
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
JPH09500087A (ja) * 1992-06-24 1997-01-07 コーテックス ファーマシューティカルズ インコーポレイテッド カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
US5760076A (en) * 1992-08-25 1998-06-02 G.D Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JP4091654B2 (ja) * 1992-08-25 2008-05-28 ジー．ディー．サール、リミテッド、ライアビリティ、カンパニー レトロウイルスプロテアーゼ阻害剤として有用なスルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド
ATE218541T1 (de) 1992-08-25 2002-06-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1994004491A1 (en) * 1992-08-25 1994-03-03 G.D. Searle & Co. N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
US6743929B1 (en) 1992-08-25 2004-06-01 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6046190A (en) * 1992-08-25 2000-04-04 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
US5830897A (en) * 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5395958A (en) * 1992-09-30 1995-03-07 Mitsubishi Kasei Corporation Cyclopropene derivatives
US6337398B1 (en) 1992-10-30 2002-01-08 G.D. Searle & Co. Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US5578606A (en) 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US5756498A (en) * 1992-10-30 1998-05-26 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5750648A (en) * 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
HU216747B (hu) * 1994-05-04 1999-08-30 Novartis Ag. Fungicid N-szulfonil- és N-szulfinil-aminosav-amidok, ezek előállítása és alkalmazása, valamint ezeket tartalmazó fungicid készítmények
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US6143747A (en) 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US5985870A (en) * 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6169085B1 (en) 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
EP1188766A1 (en) 1995-03-10 2002-03-20 G.D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776971A (en) * 1995-03-10 1998-07-07 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6667307B2 (en) 1997-12-19 2003-12-23 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6407134B1 (en) 1995-03-10 2002-06-18 G. D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
CN1530372A (zh) 1995-03-10 2004-09-22 G.D.ɪ����˾ 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
JPH11503728A (ja) * 1995-03-31 1999-03-30 シンファー ラボラトリーズ，インコーポレーティッド システイン・プロテイナーゼ阻害剤として有用な新規な４−置換−３−ペプチジル−アゼチジン−２−オン誘導体
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
US5827877A (en) * 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
ES2193615T3 (es) * 1995-10-25 2003-11-01 Senju Pharma Co .nhibidor de la angiogenesis.
US6214800B1 (en) 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
EP0928786B1 (en) * 1995-10-25 2003-01-02 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
PT861233E (pt) 1995-11-16 2000-09-29 Searle & Co Beta-amino-hidroxissulfonatos n-protegidos/n-substituidos
US5916887A (en) * 1996-09-23 1999-06-29 National Research Council Of Canada 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
US6303579B1 (en) 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
US6004933A (en) * 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
CA2348048A1 (en) * 1998-10-23 2000-05-04 Senju Pharmaceutical Co., Ltd. Method of producing peptidylaldehyde
CA2353079A1 (en) 1998-12-02 2000-06-08 Merck Frosst Canada Inc. Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
ES2421516T3 (es) 2002-11-06 2013-09-03 Dana Farber Cancer Inst Inc Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
WO2007041773A1 (en) 2005-10-07 2007-04-19 Biopharmica Ltd Sumoylation control agent and uses thereof
EP2036920B1 (en) 2006-01-11 2011-05-18 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
JP3975226B2 (ja) 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
EP2007364A4 (en) 2006-04-07 2009-11-11 Biopharmica Ltd MODULATOR OF THE TRANSCRIPTION FACTOR
EP2128167A4 (en) * 2007-03-09 2012-01-04 Univ Nagoya Nat Univ Corp PHOSPHORAMIDE COMPOUND, PROCESS FOR THE PRODUCTION THEREOF, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING AN OPTICALLY ACTIVE ALCOHOL
EP2588101B1 (en) 2010-07-02 2014-10-22 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
JPWO2019176732A1 (ja) * 2018-03-16 2021-03-25 国立大学法人東京農工大学 テトラヒドロイソキノリン環含有化合物の製造方法
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
CN110945009B (zh) * 2019-10-23 2023-10-31 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292846A (en) * 1968-11-21 1972-10-11 Zaidan Hojin Biseibutsu A process for the synthesis of leupeptins and their analogues
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
JPH0629229B2 (ja) * 1987-11-05 1994-04-20 サントリー株式会社 システインプロティナーゼ阻害剤

Also Published As

Publication number Publication date
DE69010375T2 (de) 1994-12-15
EP0393457B1 (en) 1994-07-06
DK0393457T3 (da) 1994-08-01
EP0393457A1 (en) 1990-10-24
DE69010375D1 (de) 1994-08-11
JPH02268145A (ja) 1990-11-01
US5081284A (en) 1992-01-14
JP2701932B2 (ja) 1998-01-21
ATE108187T1 (de) 1994-07-15

Similar Documents

Publication Publication Date Title
ES2058653T3 (es) Inhibidor de proteinasas.
LU91275I2 (fr) Entecavir et ses dérivés pharmaceutiquement acceptables - baraclude
SE8002634L (sv) Piperidinderivat
KR970704864A (ko) 세정제 조성물
PT88060A (pt) Processo para a preparacao de polietilenoglicol-carbaminatos
NO166589C (no) Selv-tverrbindbar akrylpolymerer.
SE7908727L (sv) Fosfinylalkanoylproliner
ZA918570B (en) Azasteroid compounds for the treatment of prostatic hypertrophy,their preparation and use
SE8002635L (sv) Piperidinderivat
GR3004018T3 (es)
HUT49860A (en) Process for producing benzamide-type protease inhibitors
GR69233B (es)
DK0695755T3 (da) Pyrrolocarbazoler
HU9200292D0 (en) Process for the production of novel tetrazole derivatives and their use
PE10597A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9 sustituidas
AU579443B2 (en) New cationic surfactants based on quaternary ammonium compounds and use thereof in cleaning agents
DE3372364D1 (en) 1-carboxyalkanoylperhydroindole-2-carboxylic acids and derivatives
CA2103072A1 (en) Pleuromutilin derivatives
ES2034324T3 (es) Procedimiento de sintesis industrial de alfa amino diacidos n alquilados o de esteres de ellos.
NO900732L (no) Arylalkylaminforbindelser.
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
FI914525A0 (fi) Foerening, anvaendning och framstaellning.
ATE26268T1 (de) 2-alkoxyaminosulfonylbenzolsulfonyl-harnstoffderivate.
ATE41421T1 (de) Carbonatderivate des ananasketons.
SE7813351L (sv) Substituerade 1,5-cyklohexadien-karboxylsyraderivat

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 393457

Country of ref document: ES